John M. Maris

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Initial testing (stage 1) of the polo‐like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT‐330): A report from the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

Mitogen‐activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere‐associated protein E inhibition

J. Maris, S. Diskin, R. Wooster, 2013, International journal of cancer.

Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome

J. Maris, M. Madonna, D. Weese-Mayer, 2015, Pediatric blood & cancer.

Dexmedetomidine does not interfere with meta‐iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations

J. Maris, A. Zuppa, D. Pryma, 2017, Pediatric blood & cancer.

Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization

A. Look, J. Maris, R. Altura, 1997, Genes, chromosomes & cancer.

Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma

Su-Chun Cheng, M. Charron, R. Hawkins, 2006, Pediatric blood & cancer.

Chemoreduction in the initial management of intraocular retinoblastoma.

C. Shields, J. Maris, J. Shields, 1996, Archives of ophthalmology.

The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.

J. Maris, S. Grupp, S. Shusterman, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia

John M. Maris, Katheleen Gardiner, John H. Bushweller, 1999, Nature Genetics.